Ionis Pharmaceuticals (IONS) Innovation Day 2025 summary

Strategic vision and business transformation

• Transitioned to a fully integrated commercial-stage biotech, independently launching and commercializing medicines, with a focus on neurology and cardiometabolic diseases using RNA-targeted oligonucleotide therapeutics.

• Achieved or exceeded all key milestones set six years ago, including building a robust pipeline and commercial organization, and advancing a high-value, innovative pipeline with multiple late-stage and recently approved medicines.

• Clear roadmap to sustained positive cash flow and financial self-sufficiency by 2028, supported by $2B in cash, disciplined expense management, and efficient capital structure.

• Prioritizing wholly owned pipeline, expanding drug discovery capabilities (siRNA, new delivery platforms), and ongoing investment in technology platforms to maintain leadership.

• Focused on transforming human health through RNA-targeted medicines and next-generation gene editing approaches, leveraging deep disease biology expertise.

Pipeline progress and clinical milestones

• Six positive phase III readouts in two years, enabling four approved medicines, with more launches expected annually, and ten medicines in late-stage development.

• Achieved two independent product launches within nine months, with two more planned for 2026 and four partner launches by end of 2027.

• Upcoming launches include Olezarsen for severe hypertriglyceridemia (SHTG) and Zilganersen for Alexander disease, with NDA submission planned for Q1 2026.

• Partnered programs (e.g., pelacarsen, eplontersen) expected to deliver additional phase III readouts and launches through 2027, targeting hepatitis B, Lp(a)-driven CVD, ATTR-CM, and IgA nephropathy.

• Neurology pipeline includes 11 medicines, with focus on pediatric neurology, dementia, motor, and neuromuscular diseases, and innovative candidates like ION582 for Angelman syndrome and ION337 for Dravet syndrome.

Commercial execution and market strategy

• TRYNGOLZA (FCS) and DAWNZERA (HAE) launches are driving robust uptake, with strong patient and physician engagement, positive access dynamics, and comprehensive support programs.

• Olezarsen demonstrated 72% triglyceride reduction and 85% reduction in acute pancreatitis in SHTG, targeting a 3M+ US patient population, with US launch expected in 2026 pending approval.

• Commercial infrastructure scaling to reach 20,000 high-treating HCPs for SHTG, leveraging omnichannel and patient support programs, and building a scalable field team for blockbuster potential.

• DAWNZERA positioned as a new standard for HAE prophylaxis, with high patient preference, strong efficacy, and convenient dosing, offering the longest dosing interval.

• Zilganersen poised for rare disease pricing ($500K+), with strong advocacy and HCP support for Alexander disease launch.